SEER Stock Recent News

Seer, Inc. (NASDAQ:SEER ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants David R. Horn - President,Treasurer & CFO Kelly Gura - Corporate Participant Omid C.

Seer (SEER -2.83%), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period.

Seer, Inc. (SEER) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.35 per share a year ago.

Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph ® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Squarepoint Ops LLC reduced its position in shares of Seer, Inc. (NASDAQ:SEER – Free Report) by 46.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,156 shares of the company’s stock after selling 25,168 shares during the quarter. Squarepoint Ops LLC’s holdings in Seer were worth $67,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors also recently bought and sold shares of the company. Two Sigma Advisers LP increased its holdings in Seer by 24.2% during the 4th quarter. Two Sigma Advisers LP now owns 681,900 shares of the company’s stock worth $1,575,000 after purchasing an additional 132,800 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Seer in the fourth quarter worth approximately $114,000. Millennium Management LLC raised its stake in Seer by 9.1% in the fourth quarter. Millennium

Does Seer, Inc. (SEER) have what it takes to be a top stock pick for momentum investors? Let's find out.

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics.